# Heart Failure 2012

CONGRESS ORGANISED BY THE HEART FAILURE ASSOCIATION OF THE ESC TOGETHER WITH THE ANNUAL CONGRESS OF THE EUROPEAN SECTION OF THE INTERNATIONAL SOCIETY FOR HEART RESEARCH AND THE ESC WORKING GROUP ON MYOCARDIAL FUNCTION



EPIDEMIOLOGISTS - NURSES - INDUSTRY AFFILIATES - HEALTH CARE PROVIDERS

# ADVANCE PROGRAMME







**Myocardial Function** ESC Working Group

# Important Dates

**14 January 2012** Deadline for abstract submission



**19 March 2012** Early-bird registration deadline

**16 April 2012** Advance registration deadline

Let us also help you find accommodation with our online hotel booking service

### Follow us on



www.escardio.org/HFA

or contact us at: HFsecretariat@escardio.org

Belgrade the city of the future in Southern Europe

### Co-organising Committees

#### Board of the Heart Failure Association (HFA) of the ESC

P. Ponikowski FESC (Wroclaw, PL) S.D. Anker FESC (Berlin, DE) J. McMurray FESC (Glasgow, GB) G. Filippatos FESC (Athens, GR) B. Pieske FESC (Graz, AT) A. Maggioni FESC (Florence, IT) F. Zannad FESC (Nancy, FR)

A. Hoes (Utrecht, NL) I. Ekman NFESC (Gothenburg, SE) T. McDonagh FESC (London, GB) C. Maack (Hamburg, DE) V. Mareev (Moscow, RU) A. Mebazaa FESC (Paris, FR) President President-Elect Immediate Past-President Chairperson Clinical Section Chairperson Basic Sciences Section Secretary Treasurer

L. Neyses (Manchester, GB) Z. Papp FESC (Debrecen, HU) J. Riley NFESC (London, GB) F. Ruschitzka FESC (Zurich, CH) P. Seferovic FESC (Belgrade, RS)

#### Ex-officio

D. van Veldhuisen FESC (Groningen, NL), Editor in Chief of the European Journal of Heart Failure

#### Sui Generi

K. Dickstein FESC (Stavanger, NO), G. Hasenfuss FESC (Gottingen, DE), A. Shah FESC (London, GB)

# Council of the International Society for Heart Research (ISHR) - European Section

T. Eschenhagen FESC (Hamburg, DE) S. Harding FESC (London, GB) P. Ferdinandy (Szeged, HU) President Past-President President-Elect

#### **ESC Working Group on Myocardial Function**

D. Hilfiker-Kleiner FESC (Hannover, DE) J. Bauersachs FESC (Hannover, DE) J.-L. Balligand FESC (Brussels, BE)

Scientific Programme Committee

The HFA Board members are part of the Scientific Committee

P. Seferovic FESC (Belgrade, RS) P. Ponikowski FESC (Wroclaw, PL) S.D. Anker FESC (Berlin, DE) Z. Papp FESC (Debrecen, HU) J. Riley NFESC (London, GB) I. Ekman NFESC (Gothenburg, SE) T. Eschenhagen FESC (Hamburg, DE) D. Hilfiker-Kleiner FESC (Hannover, DE)

#### Local Committee

N. Cemerlic Adic FESC (Novi Sad, RS) M. Deljanin Ilic FESC (Nis, RS) D. Gaita FESC (Timisoara, RO) V. Kanjuh (Belgrade, RS) M. Lainscak FESC (Golnik, SI) R. Maksimovic (Belgrade, RS) Chairperson Vice-Chairperson & Treasurer Past-Chairperson

Scientific Chairperson President HFA of the ESC President-Elect HFA of the ESC HFA Basic Sciences Representative HFA Nurse Representative HFA Nurse Representative President ISHR European Section Chairperson ESC WG on Myocardial Function

D. Milicic FESC (Zagreb, HR) V. Mitrovic FESC (Bad Nauheim, DE) A.N. Neskovic FESC (Belgrade, RS) S. Pavlovic FESC (Belgrade, RS) A.D. Ristic FESC (Belgrade, RS) G. Stankovic FESC (Belgrade, RS)

### Invitation

Dear friends and colleagues,

It is our pleasure to announce that the Heart Failure Congress 2012, which will be held in Belgrade, Serbia, 19-22 May, is organised not only by the Heart Failure Association of the European Society of Cardiology (HFA of the ESC) but also in conjunction with the European Section of the International Society for Heart Research (ES-ISHR) and the ESC Working Group on Myocardial Function. The aim of our joint Scientific Committee is to create an exciting forum for both clinicians and scientists to present, hear, exchange, and discuss the most up-to-date research and clinical findings in heart failure.

The programme has been carefully planned to provide state-of-the-art information about all aspects of heart failure - from basic science, through diagnostic strategies (including imaging and biomarkers), pharmacological and device therapy, disease monitoring (both biochemical and technological) and organisation of care (with special focus on the role of nurses, pharmacists and remote monitoring).

Integration of pharmacology and technology in the era of personalised heart failure management will be the overarching theme of the programme (including the management of co-morbidities, risk models, decision support systems and cell therapy), with the interpretation and application of the latest clinical trial results given centre stage. Based on delegate feedback from previous meetings, we have ensured that these topics will be covered in a variety of formats (expert lectures in plenary sessions, interactive educational sessions with case presentations, debates and original scientific contributions) by colleagues from many different countries. Participation of young cardiologists will be stimulated and supported through the Young Investigator Award sessions for basic and clinical research and International Heart Failure Societies' joint sessions.

For those working clinically, our main objective is to provide the knowledge required for your every day practice, including the use of devices and technologies (ICD, CRT, LVADs). Our faculty will provide a practical and international perspective, incorporating the latest ESC and brand new Heart Failure guidelines. For those whose principal concern is in research, sessions dedicated to the advances in the field of biomarkers, bio-imaging, and cell therapy will be of special interest.

Belgrade is one of the most exciting and rapidly developing European capitals, famous for its natural beauty, cultural events and hospitality. It will delight you with its two rivers, beautiful lake, many monuments, parks, archaeological sites and charming local restaurants.

Add this to the opportunity to network with your colleagues and friends in a welcoming environment and you have the complete congress experience!

On behalf of the organising committee, we invite you to join us for an educational and enjoyable four days in Belgrade.

Yours sincerely,

P. Ponikowski (Wroclaw, PL), HFA President

P. Seferovic (Belgrade, RS), Heart Failure 2012 Scientific Chairperson

J. Riley (London, GB), HFA Nurse Representative

T. Eschenhagen (Hamburg, DE), President ISHR European Section S.D. Anker (Berlin, DE), HFA President-Elect Z. Papp (Debrecen, HU), HFA Basic Sciences Representative I. Ekman (Gothenburg, SE), HFA Nurse Representative

D. Hilfiker-Kleiner (Hannover, DE), Chairperson ESC WG on Myocardial Function

### General information

#### Time Zone

Belgrade is located in the Central European time zone region - GMT+2 in May.

#### Electricity

As in most cities of Continental Europe, the electricity voltage in Belgrade is 220V. Electrical outlets are standard European.

#### Currency

The official currency in Serbia is Dinar, abbreviated RSD. Money may be exchanged in all banks and post offices, as well as in authorised bureaux de change. A bureau de change is available in the congress centre as well as two ATMs.

#### Climate

The climate in Belgrade is moderate continental, with four distinct seasons. Autumn lasts longer than spring, with longer sunny and warm periods. In May, the weather usually varies between 19°C and 25°C and is mainly sunny.

#### How to get to Belgrade

Amsterdam Athens Barcelona Berlin Brussels Bucharest Cologne Copenhagen Dusseldorf Frankfurt Gothenburg Hamburg Istanbul Kiev London Milan Moscow Munich Oslo Paris Prague Rome Sofia Stockholm Vienna Zurich



Direct flights from major European and surrounding cities:

**20 minutes** by airport bus and taxi from the airport Nikola Tesla to the city centre. (average taxi fare from the airport to the city is around  $\in$ 15 - Bus A1 fare is  $\in$ 2,50 to downtown and main Railway Station).

#### **Official Airline**

STAR ALLIANCE 🔨

The **Star Alliance™ Members** are pleased to be appointed as the official airline network for Heart Failure 2012 and to offer pre-registered delegates and one accompanying person special convention discounts between 10% and 20% off applicable published Business or Economy class fares, excluding website/internet fares, senior, youth and group fares, agency discount and round the world fares.

To obtain the Star AllianceTM Conventions Plus discount, please contact your local Star Alliance member, quote the following event code: **OS02A42** and submit proof of attending the event. When making your travel plans ensure that the event code is listed on your ticket.

Please visit: www.staralliance.com/conventionplus

### Join us at Sava Centar

Congress Culture & Business Center Milentija Popovica 9 St, 11070 Belgrade - SERBIA www.savacentar.net

The Sava Centar is the largest congress and business centre in Serbia and one of the largest in Europe. It was built in 1977 as a modern building complex in one of the best areas of Belgrade, located just 10 minutes from the city centre and 20 minutes from Belgrade International Airport.



#### Getting to Sava Centar

Belgrade's trams, trains and buses make it easy to move around the city.

A particularly useful route for visitors is tram 2 which circles the city centre, connecting the train and bus stations with Trg Slavija and the Old Town.

Bus lines 17, 601 and 95 as well as tram lines 7, 9 and 13 connect the Sava Centar with various stops within the city.

## Book your hotel online on www.escardio.org/HFA

#### **Individual Hotel Booking**

Rooms are available from 19 to 22 May 2012. All other dates are upon request and subject to hotel's availability. A limited number of rooms for individual bookings are available. For the latest list of available hotels, please visit: www.escardio.org/HFA.

	Single Room	Double Room
Balkan Hotel, 4*	€111,50	€123,00
Continental Hotel Belgrade, 4*	€165,00	€185,00
Hotel Prag, 3*	€121,50	€138,00
Hotel Excelsior, 3*	€133,00	€143,00
Belgrade City Hotel, 3*	€61.50	€90,00
Hotel Srbija, 2/3*	€51,50	€73,00

Rooms will be allocated on a first-come, first-served basis. Requests made by telephone cannot be accepted. Please note that after certain price categories have been booked out, the ESC reserves the right to confirm bookings in other categories. Upon receipt of the payment, a voucher will be issued and sent by email.

#### **Group Hotel Booking**

Group bookings (from 10 rooms) are handled separately and proposals are made on request. Hotels available for groups may not be the same as for individual bookings. Please contact us by email or fax.

Heart Failure Hotels: Tel.: +33 (0)4 92 94 76 43 - Fax: +33 (0)4 92 94 76 16 Email: HFhotels@escardio.org

### Register online on www.escardio.org/HFA

- More than 10 participants, please consult the group registration pages (special fee)
- . Less than 10 participants, please consult the third party registration pages

#### The standard registration fee entitles delegates to the following:

- Entry to all scientific sessions and the Exhibition
- Entry to the Opening Ceremony and Cocktail on Saturday 19 May
- The Final Programme and the Abstract CD-Rom
- Refreshment breaks (from Sunday morning to Tuesday morning)
- 1 year subscription to the European Journal of Heart Failure (valid for 2013 in paper version) included in the following fees: standard, member of the HFA of the ESC, nurse and student

	Until 19 March 2012	Until 16 April 2012	On-site
Standard	€ 600	€715	€ 840
Member Fee*	€ 475	€ 475	€ 840
Nurse member of the HFA of the ESC	€ 120	€120	€ 300
Student member of the HFA of the ESC	€ 120	€120	€ 300
Nurse**	€ 180	€ 240	€ 300
Student**	€ 180	€ 240	€ 300
Day Ticket	€ 330	€ 330	€ 330

\*Member of the HFA of the ESC, ES-ISHR & the ESC WG on Myocardial Function - Based on 2011 subscription

\*\*Applications must be accompanied by a letter from the applicant's Head of Department confirming nurse or student status

#### If you have not registered by 16 April 2012, you will need to register on-site in Belgrade.

Heart Failure Registration: Tel.: +33 (0)4 92 94 76 12 – Fax: +33 (0)4 92 94 76 10

Email: HFregistration@escardio.org



	BELGRADE	NIS	SOMBOR	NOVI SAD	SUBOTICA	PANCEVO	PIROT
	Saturday 19 May 2012						
14:30 16:00	Best of 2011 and 2012 - International Congresses and Papers.	Pulmonary hypertension and the right ventricle in patients with heart failure.		Heart failure with preserved ejection fraction – Update 2012 - State of the art.	Coronary heart disease in heart failure: what the clinician should know.		
			Satellite	Symposia			
18:00 -			Opening Ceremony	Welcome Cocktail			
	Sunday 20 May 2012						
08:30 10:00	Atrial fibrillation and anticoagulation in heart failure.	Co-morbidities in heart failure: diabetes.	Valvular Disease. HFA Focus. Case based interactive session.	New therapeutic devices.	Paracrine signaling: who is talking to whom and how long.	Gasotransmitters and oxidative stress in the heart.	Nursing investigator award.
			Coffee Break - Exhibition	Posters Session - Moder	ated Posters		
11:00 12:30	Valvular heart disease in heart failure.	Arrhythmias in heart failure - HF specialist meets the electrophysiologist. Cross talk.	Common challenges in CRT. HFA Focus. Case based interactive session.	Twenty-five years after CONSENSUS – What have we learnt about the RAAS in heart failure?	New hope for RNA-based therapies in heart failure.	Lethal myocardial reperfusion injury: beyond mitochondrial permeability transition.	Young investigator award for clinical research.
		·	Satellite	Symposia		·	
14:15 15:45	ESC Guidelines on the diagnosis and treatment of heart failure.	Heart failure: causes not to miss. A joint session with Latin America.	Telemonitoring - Where are we now.	Savremena dijagnostika i praćenje bolesnika sa srčanom insuficijencijom.	How to approach, treat and manage pregnancy associated heart disease.	Novel aspects of Beta- Adrenergic signaling – Implications for heart failure treatment?	Young investigator award for basic science.
Coffee Break - Exhibition Posters session		Posters session - Mode	s session - Moderated Posters				
16:30 18:00	Late breaking trials 1.	Acute heart failure Clinical management in 2012.	Imaging heart failure - What clinicians need to know.	Najvažnije poruke za lečenje srčane insuficijencije iz novih preporuka i konsenzus dokumenata Evropskog udruženja kardiologa.	Exercise training in heart failure: it's worth the effort!	Sarcomeric protein alterations leading to heart failure.	Judges choice: basic science.
			Satellite	Symposia			
	Monday 21May 2012						
08:30 10:00	When drugs fail. Surgery option. A joint session with China.	The added value of biomarkers in heart failure.	Arrhythmias. HFA Focus. Case based interactive session.	Novine u lečenju srčane insuficijencije.	Integrative physiology and systems biology for clinicians.	Myocardial regeneration: what cell sources to use?	Judges choice: clinical treatment research.
			Coffee Break - Exhibition	Posters Session - Moderated Posters			
11:00 12:30	Controversies in cardiac resynchronisation therapy.	Emerging drug therapies for acute heart failure.	When drugs fail. Using devices in heart failure. HFA Focus. A joint session with HFSA.	Debata – Kontroverze u srčanoj insuficijenciji.	Nuclear remodelling and Ca2+ handling: key player in heart failure progression?	Inflammation and autoimmune reactions in heart failure: biomaker, bystander or mediator.	Judges choice: clinical research.
			Satellite	atellite Symposia			
14:15 15:45	Late breaking trials 2.	Highlights of tomorrow.	Lifestyle: frequently asked questions.	Složena klinička stanja u srčanoj insuficijenciji - prikazi bolesnika.	Calcium waves, leaks and dangerous currents.	Cancer and the heart.	ISHR abstract session.
			Coffee Break - Exhibition	Posters Session - Mode	rated Posters		
16:30 18:00	Co-morbidities in heart failure: cardiorenal syndrome.	What heart failure specialist should know about CRT.	Acute heart failure. HFA Focus. Case based interactive session.	New devices for patient monitoring.	Understanding HFpEF: lots of news!	New ways in cardioprotective strategies: effects of co-morbidities and their medication.	Mitochondria in heart failure: an important target for therapy.
	Tuesday 22 May 2012	·	·	· 	·	·	
08:30 10:00	Idiopathic dilated cardiomyopathy - Diagnosis and treatment.	Optimal management of cardiogenic shock.		Listening and responding to our patients.	Novel mechanisms of cell death or survival in heart failure.	Highlights of the congress - Basic science.	
			Coffee Break - Exhibition	Posters Session - Mode	rated Posters		
11:00 12:30	Highlights of the congress.	The real patient: heart failure in the elderly with co-morbidity.		Lokalna sesija - sve najvažnije na kongresu!	Why haven't we got any new therapy after 30 years of hypertrophy research?	Dysfunctional ion handling in heart failure – Bystander or therapeutic target?	

.

#### Attend Heart Failure 2012 to get to know what you need to know.

Our main theme this year is

"Treatment of heart failure: integrating pharmacology and technology".

### Scientific Programme

We will provide a complete programme for heart failure specialists that will enhance their knowledge, advance their skills and apprise them of the latest developments in their direct and related fields of activity. The added value of this year's programme is the collaboration with the European Section of ISHR, through a track dedicated to research for both clinicians and researchers. A further collaboration with the ESC WG on Myocardial function is an opportunity to explore specific topics with dedicated experts.

#### Main themes and objectives

#### Treatment of heart failure: integrating pharmacology and technology

Review treatment of congestion, a major unmet need in heart failure, as a main objective. Revisit biomarkers and guidelines oriented individual strategies for the most vulnerable patients. Compare your experience with the leading experts in the field of acute heart failure and optimisation of care for the most complex patients. Explore the recent advances in management of heart failure patients with diabetes, obesity, atrial fibrillation, and ventricular arrhythmias. Translate the results of the latest randomised trials into clinically detectable improved outcomes.

#### Co-morbidities and heart failure

Explore in-depth the topics of co-morbidities and heart failure - Chronic Obstructive Pulmonary Disease (COPD), diabetes, hypertension and include new areas such as cancer, cardio-renal syndrome through main sessions led by experts but also with the more practical angle of interactive educational sessions based on actual clinical cases.

#### Devices and Technology for heart failure in 2012

Discuss critical decision making in the role of ICDs and CRT implantations and therapies. Review patient selection criteria for the use of implantable LVADs for heart failure treatment. Explore the developments of telemonitoring and other monitoring management.

#### Education and Guidelines

Understand the clinical implications of the latest guidelines for the complex clinical scenarios. Learn how to improve outcomes in the heart failure population with a practical application of the HFA guidelines to assist all heart failure professionals in the frequent controversies of their daily practice.

A first presentation of the ESC Guidelines on the diagnosis & treatment of heart failure - by the HFA Task force involved in the redaction - Guidelines aim to present all the relevant evidence on a particular clinical issue in order to help physicians to weigh the benefits and risks of a particular diagnostic or therapeutic procedure. They should be helpful in everyday clinical medical decision-making.

#### Latest Updates

On devices and therapies, ongoing trials and research to understand the upcoming technologies, drugs and development in heart failure. Hear about the latest clinical trial data and patient registries.

#### Basic Science and Basic Science translated for the clinician

When researchers meet and interact with clinicians to discuss the science that will lead tomorrow's translational initiatives. Sessions aimed at researchers, PhD students and early career scientists as well as clinicians and all health care providers.

#### **Continued Medical Education**



The Heart Failure Congress 2012 is currently under review for accreditation by the European Board for Accreditation in Cardiology (EBAC) for external credits. The accreditation results will be announced online. EBAC credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA).

Detailed instructions for converting these credits to AMA PRA Category 1 Credits are available on the AMA website.

The information published in this programme is accurate at the time it goes to press. The Scientific Committee reserves the right to amend it at any time. To view all modifications after the publication date, please visit the Scientific programme online on www.escardio.org/HFA.

### Special sessions - not to be missed!

#### SATURDAY, 19 MAY 2012 - 14:30 - 16:00 Best of 2011 & 2012 - International congresses and papers.

Chairpersons: M. Komajda (Paris, FR) - P. Ponikowski (Wroclaw, PL)

- Imaging F.J. Pinto (Lisbon, PT)
- Patient care T. Jaarsma (Norrkoping, SE)
- Biomarkers A. Maisel (San Diego, US)
- Devices D.J. van Veldhuisen (Groningen, NL)
- Drugs H. Krum (Melbourne, AU)

#### MONDAY, 21 MAY 2012 - 14:15 - 15:45

#### Highlights of tomorrow.

Chairpersons: S.D. Anker (Berlin, DE) - F. Ruschitzka (Zurich, CH) Industry representatives will present highlights of their current programme of research in heart failure and their views about the field more generally. They will inform the audience about projects in the pipeline and phase II/III trials. Each presentation will be concluded by panel discussion. Questions from the audience are encouraged.

#### TUESDAY, 22 MAY 2012 - 08:30 - 10:00

**Highlights of the congress - Basic science.** Basic Science Scientific Programme 2012 in a nutshelll Experts will present highlights on the scientific content presented in Belgrade.

#### TUESDAY, 22 MAY 2012 - 11:00 - 12:30 Highlights of the congress.

- Chairpersons: P. Seferovic (Belgrade, RS) S.D. Anker (Berlin, DE) P. Ponikowski (Wroclaw, PL)
- Basic science T. Thum (Hannover, DE)
- Patient care J. Riley (London, GB)
- Diagnosis / Imaging / Pathophysiology F. Braunschweig (Stockholm, SE)
- HFpEF: heart failure with preserved ejection fraction C. Tschoepe (Berlin, DE)
- Drug treatment A.P. Maggioni (Florence, IT)
- Devices F. Ruschitzka (Zurich, CH)

#### Case based interactive sessions - HFA Focus

These sessions are based on clinical cases which will be presented and discussed with experts sitting on the panel and audience in the room. Practical step by step management of the case, do and don't, what would you do?

Concluded by recommendations based on the new ESC Guidelines on the diagnosis and treatment of heart failure.

### SUNDAY, 20 MAY 2012 - 08:30 - 10:00 Valvular disease.

HFA Focus. Case based interactive session

#### SUNDAY, 20 MAY 2012 - 11:00 - 12:30 Common challenges in CRT.

HFA focus. Case based interactive session
 Chairpersons: K. Dickstein (Stavanger, NO) - F. Ruschitzka (Zurich, CH)
 Panel - C. Stellbrink (Bielefeld, DE) - M. Gasparini (Rozzano, IT) - To be announced

#### MONDAY, 21 MAY 2012 - 08:30 - 10:00

#### Arrhythmias.

HFA Focus. Case based interactive session Chairpersons: K. Dickstein (Stavanger, NO) - F. Ruschitzka (Zurich, CH)

#### MONDAY, 21 MAY 2012 - 11:00 - 12:30

 When drugs fail - Using devices in heart failure.
 Room: 5

 HFA Focus. A joint session with the Heart Failure Society of America (HFSA)
 Society of America (HFSA)

 Chairpersons: S.D. Anker (Berlin, DE) - B.M. Massie (San Francisco, US)
 Panel - W.T. Abraham (Columbus, US) - P. Ponikowski (Wroclaw, PL) - D.J. van Veldhuisen (Groningen, NL) K. Swedberg (Goteborg, SE) - L. Warner Stevenson (Boston, US)

#### MONDAY, 21 MAY 2012 - 16:30 - 18:00

Acute heart failure. HFA Focus. Case based interactive session. Chairpersons: G.S. Filippatos (Athens, GR) - P. Ponikowski (Wroclaw, PL) Room: Belgrade

Room: Sombor

Room: Sombor

Room: Sombor

**Room: Sombor** 

Room: Nis

#### Room: Pancevo

NIL Y

Room: Sombor

#### Room: Belgrade

Chairpersons: To be announced • Anatomical imaging and myocardial ischemia testing - J.J. Bax (Leiden, NL) • Viability testing - Is it necessary? - M. Petrie (Glasgow, GB) • New drug treatment - J.T. Parissis (Athens, GR) • Revascularisation - V. Falk (Zurich, CH) • Panel discussions	
<ul> <li>SUNDAY, 20 MAY 2012 - 08:30 - 10:00</li> <li>Atrial fibrillation and anticoagulation in heart failure.</li> <li>Chairpersons: To be announced</li> <li>AF: how big is the problem? - A.P. Maggioni (Florence, IT)</li> <li>AF therapy: rate or rhythm control? - I.C. Van Gelder (Groningen, NL)</li> <li>AF therapy: when to consider ablation? - A. Auricchio (Lugano, CH)</li> <li>Anticoagulation in patients with SR vs AF? - S. Homma (New York, US)</li> <li>Novel anticoagulants and their potential for heart failure patients - G.Y.H. Lip (Birm</li> </ul>	Room: Belgrade
SUNDAY, 20 MAY 2012 - 11:00 - 12:30 Twenty-five years after CONSENSUS. What have we learnt about the RAAS in heart failure? Chairpersons: A.J.S. Coats (Norwich, GB) - B.M. Massie (San Francisco, US) • ACE inhibitors: still the gold standard? - M. Pfeffer (Boston, US) • ARBs - What can we conclude? - K. Swedberg (Gothenburg, SE) • Aldosteroner/MRA - The complete picture? - F. Zannad (Nancy, FR) • Renin inhibitors: still on trial - H. Krum (Melbourne, AU) • ARNis - More than blocking the RAAS? - J.J.V. McMurray (Glasgow, GB)	Room: Novi Sad
MONDAY, 21 MAY 2012 - 08:30 - 10:00 When drugs fail - Surgery option A joint session under construction with ESC China affiliates. Details available soon on www.escardio.org/HFA	Room: Belgrade
<ul> <li>MONDAY, 21 MAY 2012 - 08:30 - 10:00</li> <li>The added value of biomarkers in heart failure.</li> <li>Chairpersons: W.F. Peacock (Cleveland, US) - S. Von Haehling (Berlin, DE)</li> <li>Natriuretic peptides: how to use them? - A. Maisel (San Diego, US)</li> <li>Biomarkers guided therapy: targeting iron - W. Doehner (Berlin, DE)</li> <li>Pitfalls in use of biomarkers in heart failure - A.A. Voors (Groningen, NL)</li> <li>What are they needed for in heart failure - A.W. Hoes (Utrecht, NL)</li> <li>Recent additions to the biomarker portfolio - G.S. Filippatos (Athens, GR)</li> </ul>	Room: Nis
MONDAY, 21 MAY 2012 - 11:00 - 12:30 Emerging drug therapies for acute heart failure. Chairpersons: V. Mitrovic (Bad Nauheim, DE) - J. Stepinska (Warsaw, PL) • Naturietic peptide - G.S. Filippatos (Athens, GR) • Relaxin - M. Metra (Brescia, IT) • Guanylate cyclise modulators - M. Gheorghiade (Chicago, US) • RAAS inhibitors - A.P. Maggioni (Florence, IT) • Cardiac myosin activators - J.R. Teerlink (San Francisco, US)	Room: Nis
MONDAY, 21 MAY 2012 - 16:30 - 18:00 What heart failure specialist should know about CRT. Chairpersons: F. Ruschitzka (Zurich, CH) - C. Tschoepe (Berlin, DE) • How to choose the right patient - K. Dickstein (Stavanger, NO) • How to: implantation procedures - M. Gasparini (Rozzano, IT) • How to optimise follow up - Z. Kalarus (Zabrze, PL) • How to handle non-responders - C. Stellbrink (Bielefeld, DE) • Panel discussions	Room: Nis
TUESDAY, 22 MAY 2012 - 08:30 - 10:00 Idiopathic dilated cardiomyopathy - Diagnosis and treatment. Chairpersons: M. Petrie (Glasgow, GB) - A. Keren (Jerusalem, IL) • What is DCM7 - A. Keren (Jerusalem, IL) • How should we investigate it? - S. Prasad (London, GB) • How should we treat it? - M. Petrie (Glasgow, GB)	Room: Belgrade

#### SATURDAY, 19 MAY 2012 - 14:30 - 16:00 Coronary heart disease in heart failure: what the clinician should know.

### Treatment of heart failure: Integrating Pharmacology and Technology

**Room: Subotica** 

Panel discussions

#### TUESDAY, 22 MAY 2012 - 08:30 - 10:00 Optimal management of cardiogenic shock.

Chairpersons: A. Mebazaa (Paris, FR) - J. Spinar (Brno, CZ)

- Benefits of mechanical ventilation J. Masip (Barcelona, ÉS)
- Impact of medical management on outcome M. Metra (Brescia, IT)
- Indications of mechanical support M.R. Costanzo (Naperville, US)
- Organ dysfunction J.P.E. Lassus (Espoo, FI)
- Panel discussions

#### Co-morbidities and heart failure

#### SUNDAY, 20 MAY 2012 - 08:30 - 10:00 Co-morbidities in heart failure: diabetes.

Chairpersons: V. Mareev (Moscow, RU) - To be announced

- Diabetic cardiomyopathy: does it exist? W.J. Paulus (Amsterdam, NL) Consequences of diabetes and insulin resistance in heart failure - W. Doehner (Berlin, DE)
- How to treat diabetes now P. Seferovic (Belgrade, RS) New treatments and trials - J.J.V. McMurray (Glasgow, GB)
- Panel discussions

### MONDAY, 21 MAY 2012 - 16:30 - 18:00

#### Co-morbidities in heart failure: cardiorenal syndrome. Chairpersons: A.P. Maggioni (Florence, IT) - E.A. Jankowska (Wroclaw, PL)

Definition and epidemiology - A.A. Voors (Groningen, NL)

- Pathophysiology C. Ronco (Vicenza, IT)
  Management J.T. Parissis (Athens, GR)
- Anemia and iron deficiency S.D. Anker (Berlin, DE)
- Panel discussions

#### TUESDAY, 22 MAY 2012 - 11:00 - 12:30

#### The real patient: heart failure in the elderly with co-morbidity.

Chairpersons: J. Nanas (Athens, GR) - F.H. Rutten (Utrecht, NL)

- Recognising slow onset heart failure in the elderly: time for diagnostic algorithms? A.W. Hoes (Utrecht, NL)
- How to adjust drug therapy in elderly heart failure patients C. O'Connor (Durham, US)
- · Anti-coagulation in elderly heart failure patients S. Homma (New York, US)
- How do we use biomarkers (incl. kidney function) tests in the elderly C. Ronco (Vicenza, IT)
- Palliative care in the elderly patient with HFpEF and multi-morbidity S.A. Murray (Edinburgh, GB)

### Devices and Technology for heart failure in 2012

#### SUNDAY, 20 MAY 2012 - 08:30 - 10:00 New therapeutic devices.

Chairpersons: S.D. Anker (Berlin, DE) - To be announded

- Baroreceptor stimulation G. Hasenfuss (Goettingen, DE)
- Vagal nerve stimulation F. Zannad (Nancy, FR)
- Phrenic nerve stimulation P. Ponikowski (Wroclaw, PL)
- Renal sympathetic denervation D. Francis (London, GB)
- Mitral clip O.W. Franzen (Copenhagen, DK)
- Other devices
- Panel discussions

#### SUNDAY, 20 MAY 2012 - 14:15 - 15:45

#### Telemonitoring - Where are we now.

Chairpersons: To be announced

- Insights from clinical trials: telephone monitoring and nurses J. Riley (London, GB)
- Insights from clinical trials: remote patient management F. Koehler (Berlin, DE)
- Active role for patients? I. Ekman (Gothenburg, SE)
- Different models for different patients S. Von Haehling (Berlin, DE)
- Why do we need telemonitoring solutions? J.G.F. CleTand (Kingston Upon Hull, GB)

#### SUNDAY, 20 MAY 2012 - 16:30 - 18:00 Imaging heart failure - What clinicians need to know.

#### Chairpersons: F.J. Pinto (Lisbon, PT) - S. Solomon (Boston, US)

· Echocardiography - Do we need more than ejection fraction? - B.A. Popescu (Bucharest, RO)

- CMR: ever necessary? J.J. Bax (Leiden, NL)
   Nuclear: still relevant? A.N. Kitsiou (Athens, GR)
- PET/CT P.G. Camici (Milan, IT)
- Panel discussions

Room: Nis

#### Room: Belgrade

Room: Nis

#### Room: Novi Sad

Room: Sombor

#### Room: Sombor

Room: Nis

MONDAY, 21 MAY 2012 - 11:00 - 12:30 Controversies in cardiac resynchronisation therapy. Chairpersons: K. Dickstein (Stavanger, NO) - To be announced • Atrial fibrillation - A. Auricchio (Lugano, CH) • Non left bundle branch block - C. Stellbrink (Bielefeld, DE) • When to upgrade a conventional pacemaker - C. Linde (Stockholm, SE) • Narrow QRS - F. Ruschitzka (Zurich, CH) • Left ventricular ejection fraction >35 - D.A. Kass (Baltimore, US)	Room: Belgrade
MONDAY, 21 MAY 2012 - 16:30 - 18:00 New devices for patient monitoring. Chairpersons: F. Koehler (Berlin, DE) - P. Seferovic (Belgrade, RS) - Fluid balance / Impedance - D.J. van Veldhuisen (Groningen, NL) - Haemodynamics sensing - W.T. Abraham (Columbus, US) - Rhythm assessments - F. Braunschweig (Stockholm, SE) - Home biomarkers - A. Maisel (San Diego, US) - How to integrate new device and manage information - J.G.F. Cleland (Kingston Upon Hull,	<b>Room: Novi Sad</b>
Education and Guidelines	
SATURDAY, 19 MAY 2012 - 14:30 - 16:00 Pulmonary hypertension and the right ventricle in patients with heart failure. Session details to be announced	Room: Nis
SUNDAY, 20 MAY 2012 - 11:00 - 12:30 Valvular heart disease in heart failure. Chairpersons: To be announced How to assess valvular heart disease? - A. Vahanian (Paris, FR) Management of mitral regurgitation - O. Alfieri (Brescia, IT) Management of aortic stenosis - R. Lange (Munchen, DE) Management of tricuspid regurgitation - A. Pitsis (Thessaloniki, GR) Panel discussions	Room: Belgrade
SUNDAY, 20 MAY 2012 - 11:00 - 12:30 Arrhythmias in heart failure - HF specialist meets the electrophysiologist. Cross talk Chairpersons: J. Brugada Terradellas (Barcelona, ES) - A. Cohen-Solal (Paris, FR) Atrial fibrillation Heart failure specialists' view point - R. Dabrowski (Warsaw, PL) Electrophysiologists' view point - M. Haissaguerre (Pessac, FR) Ventricular tachycardia Heart failure specialists' view point - To be announced Electrophysiologists' view point - A. Auricchio (Lugano, CH)	Room: Nis
SUNDAY, 20 MAY 2012 - 14:15 - 15:45 Guidelines. Chairperson: J.J.V. McMurray (Glasgow, GB) Exclusive presentation of the new ESC Guidelines on Heart Failure	Room: Belgrade
SUNDAY, 20 MAY 2012 - 14:15 - 15:45 Heart failure: causes not to miss. A join session currently under construction with ESC Latin America affiliates. Details available soon on www.escardio.org/HFA	Room: Nis
Latest Updates	
<ul> <li>SATURDAY, 19 MAY 2012 - 14:30 - 16:00</li> <li>Heart failure with preserved ejection fraction - Update 2012 - State of the art.</li> <li>Chairpersons: W.J. Paulus (Amsterdam, NL) - D.L. Brutsaert (Antwerp, BE)</li> <li>Pathophysiology of HFpEF - What is new and clinically relevant? - D.A. Kass (Baltimore, US)</li> <li>Diagnosis - Is it really heart failure? - B.M. Pieske (Graz, AT)</li> <li>Biomarkers and imaging - Can they assure the diagnosis? - S. Solomon (Boston, US)</li> <li>Current and future management of HFpEF - J.J.V. McMurray (Glasgow, GB)</li> <li>Panel discussions</li> </ul>	Room: Novi Sad
SUNDAY, 20 MAY 2012 - 16:30 - 18:00 Late breaking trials 1.	Room: Belgrade
Chairpersons: S.D. Anker (Berlin, DE) - K. Swedberg (Gothenburg, SE)	

Chairpersons: S.D. Anker (Berlin, DE) - K. Swedberg (Gothenburg, SE) Latest trials: presentation by investigators followed by a discussant review and questions from audience and chairpersons.

#### SUNDAY, 20 MAY 2012 - 16:30 - 18:00

#### Acute heart failure - Clinical management in 2012.

- Chairpersons: M. Gheorghiade (Chicago, US) A. Mebazaa (Paris, FR)
- Pre-hospital treatment F.H. Rutten (Utrecht, NL) Emergency department management - W.F. Peacock (Cleveland, US)
- ICU management: special cases of cardiogenic shock M.R. Costanzo (Naperville, US)
- In hospital management P. Ponikowski (Wroclaw, PL)
- Post discharge management G.S. Filippatos (Athens, GR)

### MONDAY, 21 MAY 2012 - 14:15 - 15:45

#### Late breaking trials 2.

#### Chairpersons: P. Ponikowski (Wroclaw, PL) - P. Seferovic (Belgrade, RS) Latest trials: presentation by investigators followed by a discussant review and questions from audience and chairpersons.

#### Patient care

#### MONDAY, 21 MAY 2012 - 14:15 - 15:45

#### Lifestyle: frequently asked questions.

Chairpersons: J. Riley (London, GB) - A.W. Hoes (Utrecht, NL) - I. Ekman (Gothenburg, SE)

- Sex T. Jaarsma (Norrkoping, SE)
- Diet M. Lainscak (Golnik, ŠI)
- Driving and travel T.A. McDonagh (London, GB)
- Exercise V. Conraads (Edegem, BE)

#### TUESDAY, 22 MAY 2012 - 08:30 - 10:00 Listening and responding to our patients.

#### Chairpersons: T.A. McDonagh (London, GB) - A. Wolf (Gothenburg, SE)

- Delivering person-centered care: a new way of organising care? I. Ekman (Gothenburg, SE)
- Caring for relatives A. Stromberg (Linkoping, SE)
- Providing emotional support To be announced
- Supporting the expert patient: a new role for technology? J. Riley (London, GB)
- Panel discussions

### Basic Science Translated for the Clinician

#### SUNDAY, 20 MAY 2012 - 14:15 - 15:45

How to approach, treat and manage pregnancy associated heart disease. Chairpersons: A.M. Shah (London, GB) - S. Janssens (Leuven, BE)

- Definition and epidemiology of pregnancy-associated heart disease M. Schaufelberger (Gothenburg, SE)
- Update on the European peri-paertum cardiomyopathy registry A.P. Maggioni (Florence, IT)
- Impaired endothelial to cardiomyocyte cross-talk responsible for slow recovery from PPCM
- D. Hilfiker-Kleiner (Hannover, DE
- New biomarkers for diagnosis and risk stratification of women with heart disease in pregnancy V. Reaitz-Zaarosek (Berlin, DE)
- Multi-media approach implementing cutting-edge technology into educational and preventative health programme in women - K. Sliwa-Hahnle (Cape Town, ZA)

#### SUNDAY, 20 MAY 2012 - 16:30 - 18:00

#### Exercise training in heart failure: it's worth the effort!

- Chairpersons: M.F. Piepoli (Piacenza, IT) D. Gaita (Timisoara, RO)
- Physical activity and risk of heart failure A.J.S. Coats (Norwich, GB)
- Exercise training and cardiac remodelling D.J.G.M. Duncker (Rotterdam, NL)
- Exercise training and vascular remodelling A.H.P. Linke (Leipzig, DE)
- Clinical trial evidence for exercise training in heart failure C. O'Connor (Durham, US) · How to implement exercise training in clinical practice - V. Conraads (Edegem, BE)

#### MONDAY, 21 MAY 2012 - 14:15 - 15:45 Calcium waves, leaks and dangerous currents.

Chairpersons: F.R. Heinzel (Graz, AT) - L. Neyses (Manchester, GB)

- Roles of RyR2 and SERCA2 in arrhythmogenesis D.A. Eisner (Manchester, GB)
- CaMKII as a critical modulator of SR function To be announced
- Inherited SR-linked arrhythmias S.G. Priori (Pavia, IT)
- Translation into clinical arena G. Hasenfuss (Gottingen, DE)

### MONDAY, 21 MAY 2012 - 16:30 - 18:00

Understanding HFpEF: lots of news! Chairpersons: S. Solomon (Boston, US) - B.M. Pieske (Graz, AT)

- Atrial function V. Melenovsky (Prague, CZ)
- New imaging modalities in HFpEF E. Kraigher-Krainer (Graz, AT)
- Exercise testing M.P. Frenneaux (Aberdeen, GB)
- Invasive haemodynamics D.A. Kass (Baltimore, US)
- New drugs in the pipeline for HfpEF M. Pfeffer (Boston, US)

#### Room: Belgrade

### Room: Sombor

#### Room: Novi Sad

#### Room: Subotica

### Room: Subotica

### Room: Subotica

#### Room: Subotica

#### Room: Nis

#### TUESDAY, 22 MAY 2012 - 11:00 - 12:30

Why haven't we got any new therapy after 30 years of hypertrophy research?

- Chairpersons: T. Eschenhagen (Hamburg, DE) S.E. Harding (London, GB)
- Insights into hypertophic remodelling State of the art L. Neyses (Manchester, GB)
- We are on the right track Therapeutic success will come To be announced
   The concept is wrong No way into new therapies To be announced
- Integration from a clinical perspective M. Pfeffer (Boston, US)
- Integration from a clinical perspective M. Piener (Boston, Os)

#### **Basic Science**

#### SUNDAY, 20 MAY 2012 - 08:30 - 10:00

#### Paracrine signaling: who is talking to whom and how long. Chairpersons: T. Thum (Hannover, DE) - D.L. Brutsaert (Antwerp, BE)

Neuregulin-1 and its potential role in the control of cardiac function - G.W.A. De Keulenaer (Wilrijk, BE)

- The importance of the cardiac microenvironement D. Hilfiker-Kleiner (Hannover, DE)
- Cardiac metabolism and VEGF regulation To be announced
- Myofibroblasts in heart failure mediators of remodelling and arrhythmogeneicity? To be announced
- Fibroblast myocyte interactions S. Engelhardt (Munich, DE)

#### SUNDAY, 20 MAY 2012 - 08:30 - 10:00

#### Gasotransmitters and oxidative stress in the heart.

- Chairpersons: P. Ferdinandy (Szeged, HU) G. Valen (Oslo, NO)
- Neuronal NO Synthase-Derived NO To be announced
- Novel pharmacological approaches targeting NO J. Widder (Wurzburg, DE)
- Hydrogen sulfide signaling in the heart G.F. Baxter (Cardiff, GB)
- Carbon monoxide signaling in the heart C. Peers (Leeds, GB)
- Modulating NOS uncoupling: a new therapeutic avenue? A. Moens (Hoensbroek, NL)

#### SUNDAY, 20 MAY 2012 - 11:00 - 12:30 New hope for RNA-based therapies in heart failure.

Chairpersons: S. Engelhardt (Munich, DE) - M. Mayr (London, GB)

- Targeting non-coding RNAs implicated in cardiomyocyte regeneration M. Giacca (Trieste, IT)
- Targeting microRNA implicated in cardiomyocyte function L.J. De Windt (Maastricht, NL)
- Targeting fibrosis microRNAs to treat heart failure T. Thum (Hannover, DE)
- Correcting gene defects in muscular dystrophy T. Voit (Paris, FR)
- Alternative approaches: AAV-mediated gene transfer to treat heart failure R.J. Hajjar (New York, US)

#### SUNDAY, 20 MAY 2012 - 11:00 - 12:30

#### Lethal myocardial reperfusion injury: beyond mitochondrial permeability transition. Room: Pancevo

Chairpersons: F. Di Lisa (Padua, IT) - R. Schulz (Giessen, DE)

- Cardiomyocyte cell death: apoptósis, necrosis, autophagy D.J. Hausenloy (London, GB)
- Factors determining the type of cell death during ischemia/reperfusion D. Garcia-Dorado (Barcelona, ES)
- Microvascular factors in myocardial reperfusion injury G. Heusch (Essen, DE)
- Mitochondrial permeability transition: not only a cell death determinant J. Molkentin (Cincinnati, US)
- Ischemia-reperfusion injury: which therapies after 20 years of research? H.N. Sabbah (Detroit, US)

#### SUNDAY, 20 MAY 2012 - 14:15 - 15:45

### Novel aspects of Beta-Adrenergic signaling - Implications for heart failure treatment? Room: Pancevo Chairpersons: S.E. Harding (London, GB) - To be announced

- Redistribution of beta-adrenergic receptors in heart failure V.O. Nikolaev (Wurzburg, DE)
- PI3 kinase and cAMP signaling microdomains E. Hirsch (Turin, IT)
- Role of phosphodiesterase 4 for cardiac arrhythmias G. Vandecasteele (Chatenay-Malabry, FR)
- Beta-blockers old dogs, new tricks? C. Maack (Hamburg, DE)
- Heart rate and heart rate modulation in HfpEF M. Boehm (Hamburg, DE)

#### SUNDAY, 20 MAY 2012 - 16:30 - 18:00

#### Sarcomeric protein alterations leading to heart failure.

Chairpersons: T. Eschenhagen (Hamburg, DE) - W.J. Paulus (Amsterdam, NL)

- Post-translational modifications of sarcomeric proteins in cardiac disease J.C. Kentish (London, GB)
- Regional heterogeneity in sarcomere function and cardiac disease Z. Papp (Debrecen, HU)
- Impaired Frank-Starling mechanism in hypertrophy and failure? J. van der Velden (Amsterdam, NL)
- Increased energy usage of the sarcomeres as cause of cardiac hypertrophy C. Poggesi (Florence, IT)

#### MONDAY, 21 MAY 2012 - 08:30 - 10:00

#### Integrative physiology and systems biology for clinicians.

- Chairpersons: B.K. Pedersen (Copenhagen, DK) A.R. Pries (Berlin, DE)
- Introduction for clinicians L. Neyses (Manchester, GB)
- Systems biological strategies in cardiovascular disease M. Oresic (Espoo, FI)
- Clinical proteomics in cardiovascular disease F. Pinet (Lille , FR)
- Clinical metabolomics of LV remodelling M. Mamas (Manchester, GB)
- Reclassification of cardiovascular risk using integrated clinical and molecular biosignatures To be announced

#### **Room: Subotica**

Room: Pancevo

#### **Room: Subotica**

# Room: Pancevo

#### **Room:** Subotica

#### Room: Subotica

Room: Subotica

#### 17

#### MONDAY, 21 MAY 2012 - 08:30 - 10:00

Myocardial regeneration: what cell sources to use?

- Chairpersons: T. Eschenhagen (Hamburg, DE) To be announced
- The potential of epicardial cells To be announced
- Embryonic and gonadal stem cells: where are we in 2012? W.-H. Zimmermann (Gottingen, DE)
- IPS cells: potential and pitfalls K.-L. Laugwitz (Munich, DE)
- Myocardial regeneration: do we need cells or the factors that they produce? K.C. Wollert (Hannover, DE)
- Clinical perspective of adult bone marrow cell therapy S. Janssens (Leuven, BE)

#### MONDAY, 21 MAY 2012 - 11:00 - 12:30

#### Nuclear remodelling and Ca2+ handling: key player in heart failure progression? Room: Subotica

- Chairpersons: B.M. Pieske (Graz, AT) R. Fischmeister (Chatenay-Malabry, FR)
- The concept of excitation-transcription coupling D.M. Bers (Davis, US) Structural remodelling of the nucleus in hypertrophy and heart failure - J. Kockskaemper (Marburg, DE)
- Altered ion handling of the nucleus in hypertrophy and failure S. Ljubojevic (Graz, AT)
- Surface-to nucleus communication: new insights into IP3-dependent regulation of cardiac remodelling M.Bootman (GB)
- Biology and therapeutic implications of HDACs in the heart. T.A. McKinsey (Denver, US)

#### MONDAY, 21 MAY 2012 - 11:00 - 12:30

#### Inflammation and autoimmune reactions in heart failure: biomarker, bystander or mediator. Room: Pancevo Chairpersons: M. Fu (Gothenburg, SE) - R. Jahns (Wurzburg, DE)

- Inflammation and immunity: how it occurs and how to measure it? G.K. Hansson (Stockholm, SE)
- Metabolic consequences of inflammation in heart failure? E.A. Jankowska (Wroclaw, PL)
- Autoantibodies İmmunoabsorption and epitope-mimicking cyclic peptides R. Jahns (Wurzburg, DE)
- Toll-like receptors as potential therapeutic targets in cardiac dysfunction D. Mann (St. Louis, US)
- Insight from anti-inflammatory and immunregulatory trials in chronic heart failure P. Aukrust (Oslo, NO)

#### MONDAY, 21 MAY 2012 - 14:15 - 15:45

#### Cancer and the heart.

Chairpersons: D. Hilfiker-Kleiner (Hannover, DE) - E. Hirsch (Turin, IT)

- Cardiac function in cancer patients What do we know? S. Von Haehling (Berlin, DE)
- Mechanisms of chemotherapy induced cardiotoxicity T.L. Force (Philadelphia, US)
- Using cardiac biomarkers & treating cardiotoxicity in cancer D. Cardinale (Milan, IT)
- Progressive loss of cardiac function and muscle in cancer cachexia; time to treat the heart! J. Springer (Berlin, DE)
- Treating cancer patients with heart failure drugs: clinical data A.J.S. Coats (Norwich, GB)

#### MONDAY, 21 MAY 2012 - 16:30 - 18:00

New ways in cardioprotective strategies: effects of co-morbidities and their medication. Room: Pancevo

- Chairpersons: B.J. Mcdermott (Belfast, GB) G. Heusch (Essen, DE) Cardioprotective signaling in aging R. Schulz (Giessen, DE)
- Drug-induced inhibition of endogenous cardioprotection: new safety considerations E. Golomb (IL)
- Cardioprotective signaling in diabetes D.J. Hausenloy (London, GB)
- Effects of hyperlipidemia and statins on cardioprotective signaling P. Ferdinandy (Szeged, HU)
- The role of mitochondrial MAO in cardioprotection F. Di Lisa (Padua, IT)

#### MONDAY, 21 MAY 2012 - 16:30 - 18:00

#### Mitochondria in heart failure: an important target for therapy.

- Chairpersons: D.M. Bers (Davis, US) C. Maack (Hamburg, DE)
- Energy metabolism in heart failure R.F. Ventura-Clapier (Chatenay-Malabry, FR)
- Abnormalities of structure and function of mitochondria in heart failure H.N. Sabbah (Detroit, US)
- Mitochondria & tissue iron S. Von Haehling (Berlin, DE)
- Mitochondria DNA mutations and heart failure L. Bindoff (Bergen, NO)
- Oxidative stress and mitochondria DNA damage in heart failure A.J. Murray (Oxford, GB)

#### TUESDAY, 22 MAY 2012 - 08:30 - 10:00 Novel mechanisms of cell death or survival in heart failure.

Chairpersons: F. Di Lisa (Padua, IT) - A.M. Shah (London, GB)

- Mitophagy and sterile inflammation K.Otsu (Osaka, JP)
- The mitochondrial PTP and cell necrosis J. Molkentin (Cincinnati, US)
- Fatty acids trigger mitochondrion-dependent necrosis F. Madeo (Graz, AT)
- PI3K signaling and myocardial cell death E. Hirsch (Turin, IT)
- The protective neuregulin-1 / Erb axis G.W.A. De Keulenaer (Wilrijk, BE)

#### TUESDAY, 22 MAY 2012 - 11:00 - 12:30

#### Dysfunctional ion handling in heart failure - Bystander or therapeutic target?

- Chairpersons: D.A. Eisner (Manchester, GB) G. Hasenfuss (Gottingen, DE)
- Dysfunctional ino handling in heart failure State of the art D.M. Bers (Davis, US)
- · Pharmacological modulation of the NCX What is the evidence? G. Antoons (Leuven, BE)
- Mechanosensitive ion channels in the failing heart Focus on TRP channels T. Gudermann (Munich, DE)
- Alterations of atrial Ca2+ handling in heart failure Cause or consequence for atrial fibrillation?
- U. Schotten (Maastricht, NL)

### Room: Pancevo

Room: Pancevo

### Room: Pirot

Room: Pancevo

#### Local Language Sessions

Sessions held in Serbo-Croatian only, no translation available.

#### SUNDAY, 20 MAY 2012 - 14:15 - 15:45

Savremena dijagnostika i praćenje bolesnika sa srčanom insuficijencijom.

- Chairpersons: N. Cemerlic Adic (Sremska Kamenica, RS), D. Vulic (Banja Luka, BA)
- · Kako primeniti biomarkere u dijagnostici i lečenju srčane insuficijencije? S. Dodic (Sremska Kamenica, RS)
- Značaj ehokardiografije u proceni bolesnika sa srčanom insuficijencijom A.N. Neskovic (Belgrade, RS) Magnetna rezonanca i multi-slajsna kompjuterizovana tomografija u srčanoj insuficijenciji
- R. Maksimovic (Belgrade, RS) Od elektrokardiografije do invazivne dijagnostike u proceni srčane insuficijencije - V. Vukcevic (Belgrade, RS)

#### SUNDAY, 20 MAY 2012 - 16:30 - 18:00

Najvažnije poruke za lečenje srčane insuficijencije iz novih preporuka i konsenzus dokumenata Evropskog udruženja kardiologa

Chairpersons: Z. Vasiljević (Belgrade, RS), V. Mitrović (Bad Nauheim, DE)

- Šta je novo u preporukama za srčanu insuficijenciju Evropskog udruženja kardiologa 2012? P.M. Seferovic (Belgrade, RS)
- Peripartalna kardiomiopatija M. Deljanin-Ilic (Nis, RS)
- Lečenje dislipidemija i dijabetesa kod bolesnika sa srčanom insuficijencijom N.M. Lalic (Belgrade, RS)
- Pejsmejkeri, kardioverter defibrilatori i drugi implantabilni uredaji u lečenju srčane insuficijencij
- G. Milasinovic (Belgrade, RS)

#### MONDAY, 21 MAY 2012 - 08:30 - 10:00

#### Novine u lečenju srčane insuficijencije.

Chairpersons: E. Raljevic (Sarajevo, BA), M. Pavlović (Nis, RS)

- Akutna srčana insuficijencija: šavremeni terapijski pristup V. Mitrovic (Bad Nauheim, DE)
- Savremena medikamentozna terapija hronične srčane insuficijencije D. Milicic (Zagreb, HR)
- Nekoronarne perkutane intervencije u lečenju srčane insuficijencije S. Kedev (Skoplje, MK)
- Značaj kardiohirurgije u lečenju srčane insuficijencije kada nije dostupna transplantacija srca: indikacije, tehnike, dugoročni rezultati - N. Radovanovic (Belgrade, RS)

#### MONDAY, 21 MAY 2012 - 11:00 - 12:30

Debata - kontroverze u srčanoj insuficijenciji. Room: Novi Sad Chairpersons: M. Dilic (Sarajevo, BA), S. Ilic (Nis, RS) Lečenje stabilne angine pectoris kod bolesnika sa hroničnom srčanom insuficijencijom: medikamentozni vs. interventni pristup.

- Prednost lekovima Z. Vasiljevic (Belgrade, RS)
- Prednost interventnom pristupu G. Stankovic (Belgrade, RS)

Smanjenje srčane frekvence kod bolesnika sa srčanom insuficijencijom:

uloga ivabradina i titracije beta blokatora.

- Za P.M. Seferovic (Belgrade, RS)
- Protiv M. Ostojic (Belgrade, RS)

#### MONDAY, 21 MAY 2012 - 14:15 - 15:45

#### Složena klinička stanja u srčanoj insuficijenciji - prikazi bolesnika.

Chairpersons: V. Kanjuh (Belgrade, RS), S. Dimkovic (Belgrade, RS)

- Ishemijski cerebrovaškularni insult i srčana insuficijencija V. Kostić (Belgrade, RS)
- Prevencija i lečenje bubrežne slabosti kod bolesnika sa srčanom insuficijencijom V. Stefanović (Nis, RS)
- Srce i srčana slabost u autoimunim reumatskim bolestima M. Matucci-Cerinic (Florence, IT)
- Srčana slabost u plućnoj hipertenziji: etiopatogenetski principi i novi pravci lečenja N. Škoro-Šajer (Vienna, AT)

#### TUESDAY, 22 MAY 2012 - 11:00 - 12:30

#### Lokalna sesija - sve najvažnije na kongresu!

Chairpersons: F. Kenda (Ljubljana, SI) - D. Milicic (Zagreb, HR)

- Bazične D. Jakovljevic (Newcastle Upon Tyne, GB)
- Nega bolesnika M. Lainscak (Golnik, SI)
- Dijagnostika, vizualizacione metode i patofiziologija L. Jovovic (Belgrade, RS)
- Medikamentozna terapija A.D. Ristic (Belgrade, RS)
- Pejsmejkeri, defibrilatori i drugi implantabilni uredjaji S.U. Pavlovic (Belgrade, RS)

Room: Novi Sad

### Scientific Programme

**Be part of your Congress, participate actively in the Scientific Programme!** Abstract submission: 15 November 2011 - 14 January 2012

#### **Abstract-based Sessions**

#### **Oral sessions**

#### Young Investigators Award (YIA) Sessions - Basic Science and Clinical

A competition designed for abstract submitters / presenters 35 years old or under. Finalists will present their research in oral YIA sessions moderated by two chairpersons and a panel of experts to judge the presentations and determine a First Prize Winner (€1000) and two Runners-Up (€250). YIA abstract presenters will benefit from free registration to the congress.

#### Nursing Investigator Award (NIA) Session

Submitting the abstract under NIA will automatically entitle you to take part in the Nursing award competition. Selected finalists will present their findings in oral session moderated by two chairpersons and a panel of expert judges who will determine a First Prize Winner ( $\in$ 1000) and two Runners-Up ( $\in$ 250). NIA abstract presenters will benefit from free registration to the congress. There is no age limitation.

#### Oral Abstract Presentation - Basic Science and Clinical

New format in 2012, fast-paced and interactive! Flash presentations on the research highlights: Aim / Methods / Results, followed by discussions animated by two experts chairing the session.

#### Moderated Posters sessions

The content of abstracts considered to be of special interest will be displayed in the form of a poster in a dedicated Moderated Poster Area. Presenters will briefly discuss keypoints of their research with two moderators in front of an appreciative audience during official coffee breaks. Posters are available for consultation throughout the poster session

#### Posters sessions

These sessions provide a visual display of research highlights. This format allows a maximum of viewing time for the research and peer to peer interaction. A very popular platform where our community truly comes together to meet and exchange knowledge - Five half-day sessions are planned.

#### **Clinical cases**

A session dedicated to presentations of your clinical case. Submit your abstract under this category for an opportunity to share your experience and interact with your colleagues and peers.

#### HFA Grants Become your Heart Failure Association champion!

By submitting an abstract you may be eligible for one of the 30 HFA Grants distributed by the Heart Failure Association in cooperation with your national Heart Failure Society or Working Group! Read the application...

#### Because science, research and great trials are always in the making

Late Breaking Clinical Trials Late Breaking Research Trials On-going Clinical Trials

Online application forms available on 1st February 2012

Additional information on the dedicated programmes available on the website.

#### Language

The official language of the Congress is English. All lectures and presentations will be held in English, except six marked local language sessions. No translation will be provided.



# The Heart Failure Association of the ESC is a non-profit professional organisation for:

Cardiologists, Internists, Physicians, General Practitioners, Basic Scientists, Epidemiologists, Nurses, Industry Affiliates, Health Care Providers

### Knowledge

- Workshops
- Scientific Papers
- Guidelines
- Committees
- Research
- Journal

### Networking

- Annual Congress
- Winter Research Meeting
  - National Societies
  - Heart failure
  - management centres
  - Social media

### GET INVOLVED! JOIN THE HFA of the ESC

### **Membership benefits**

- The HFA quarterly newsletter
- Reduced registration fee for HFA Congress
- Reduced subscription to the EJHF
- Voting for HFA Board
- Opportunity to join committees



#### **CONTACT THE HFA**

Education

Educational

Training programmes

On Line Education

Nurse Fellowship

Patient website

Research Fellowship

hfa@escardio.org www.escardio.org/HFA